Cargando…

MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients

Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Horak, Josef, Dolnikova, Alexandra, Cumaogullari, Ozge, Cumova, Andrea, Navvabi, Nazila, Vodickova, Ludmila, Levy, Miroslav, Schneiderova, Michaela, Liska, Vaclav, Andera, Ladislav, Vodicka, Pavel, Opattova, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618941/
https://www.ncbi.nlm.nih.gov/pubmed/36324569
http://dx.doi.org/10.3389/fonc.2022.959407
_version_ 1784821164403589120
author Horak, Josef
Dolnikova, Alexandra
Cumaogullari, Ozge
Cumova, Andrea
Navvabi, Nazila
Vodickova, Ludmila
Levy, Miroslav
Schneiderova, Michaela
Liska, Vaclav
Andera, Ladislav
Vodicka, Pavel
Opattova, Alena
author_facet Horak, Josef
Dolnikova, Alexandra
Cumaogullari, Ozge
Cumova, Andrea
Navvabi, Nazila
Vodickova, Ludmila
Levy, Miroslav
Schneiderova, Michaela
Liska, Vaclav
Andera, Ladislav
Vodicka, Pavel
Opattova, Alena
author_sort Horak, Josef
collection PubMed
description Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pathways are significantly involved in the mechanisms of chemoresistance. MRE11, a part of the MRN complex involved in double-strand break (DSB) repair, is connected to colorectal cancer (CRC) patients’ prognosis. Our previous results showed that single-nucleotide polymorphisms (SNPs) in the 3′ untranslated region (3′UTR) microRNA (miRNA) binding sites of MRE11 gene are associated with decreased cancer risk but with shorter survival of CRC patients, which implies the role of miRNA regulation in CRC. The therapy of colorectal cancer utilizes oxaliplatin (oxalato(trans-l-1,2-diaminocyclohexane)platinum), which is often compromised by chemoresistance development. There is, therefore, a crucial clinical need to understand the cellular processes associated with drug resistance and improve treatment responses by applying efficient combination therapies. The main aim of this study was to investigate the effect of miRNAs on the oxaliplatin therapy response of CRC patients. By the in silico analysis, miR-140 was predicted to target MRE11 and modulate CRC prognosis. The lower expression of miR-140 was associated with the metastatic phenotype (p < 0.05) and poor progression-free survival (odds ratio (OR) = 0.4, p < 0.05). In the in vitro analysis, we used miRNA mimics to increase the level of miR-140 in the CRC cell line. This resulted in decreased proliferation of CRC cells (p < 0.05). Increased levels of miR-140 also led to increased sensitivity of cancer cells to oxaliplatin (p < 0.05) and to the accumulation of DNA damage. Our results, both in vitro and in vivo, suggest that miR-140 may act as a tumor suppressor and plays an important role in DSB DNA repair and, consequently, CRC therapy response.
format Online
Article
Text
id pubmed-9618941
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96189412022-11-01 MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients Horak, Josef Dolnikova, Alexandra Cumaogullari, Ozge Cumova, Andrea Navvabi, Nazila Vodickova, Ludmila Levy, Miroslav Schneiderova, Michaela Liska, Vaclav Andera, Ladislav Vodicka, Pavel Opattova, Alena Front Oncol Oncology Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pathways are significantly involved in the mechanisms of chemoresistance. MRE11, a part of the MRN complex involved in double-strand break (DSB) repair, is connected to colorectal cancer (CRC) patients’ prognosis. Our previous results showed that single-nucleotide polymorphisms (SNPs) in the 3′ untranslated region (3′UTR) microRNA (miRNA) binding sites of MRE11 gene are associated with decreased cancer risk but with shorter survival of CRC patients, which implies the role of miRNA regulation in CRC. The therapy of colorectal cancer utilizes oxaliplatin (oxalato(trans-l-1,2-diaminocyclohexane)platinum), which is often compromised by chemoresistance development. There is, therefore, a crucial clinical need to understand the cellular processes associated with drug resistance and improve treatment responses by applying efficient combination therapies. The main aim of this study was to investigate the effect of miRNAs on the oxaliplatin therapy response of CRC patients. By the in silico analysis, miR-140 was predicted to target MRE11 and modulate CRC prognosis. The lower expression of miR-140 was associated with the metastatic phenotype (p < 0.05) and poor progression-free survival (odds ratio (OR) = 0.4, p < 0.05). In the in vitro analysis, we used miRNA mimics to increase the level of miR-140 in the CRC cell line. This resulted in decreased proliferation of CRC cells (p < 0.05). Increased levels of miR-140 also led to increased sensitivity of cancer cells to oxaliplatin (p < 0.05) and to the accumulation of DNA damage. Our results, both in vitro and in vivo, suggest that miR-140 may act as a tumor suppressor and plays an important role in DSB DNA repair and, consequently, CRC therapy response. Frontiers Media S.A. 2022-10-17 /pmc/articles/PMC9618941/ /pubmed/36324569 http://dx.doi.org/10.3389/fonc.2022.959407 Text en Copyright © 2022 Horak, Dolnikova, Cumaogullari, Cumova, Navvabi, Vodickova, Levy, Schneiderova, Liska, Andera, Vodicka and Opattova https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Horak, Josef
Dolnikova, Alexandra
Cumaogullari, Ozge
Cumova, Andrea
Navvabi, Nazila
Vodickova, Ludmila
Levy, Miroslav
Schneiderova, Michaela
Liska, Vaclav
Andera, Ladislav
Vodicka, Pavel
Opattova, Alena
MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title_full MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title_fullStr MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title_full_unstemmed MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title_short MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
title_sort mir-140 leads to mre11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618941/
https://www.ncbi.nlm.nih.gov/pubmed/36324569
http://dx.doi.org/10.3389/fonc.2022.959407
work_keys_str_mv AT horakjosef mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT dolnikovaalexandra mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT cumaogullariozge mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT cumovaandrea mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT navvabinazila mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT vodickovaludmila mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT levymiroslav mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT schneiderovamichaela mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT liskavaclav mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT anderaladislav mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT vodickapavel mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients
AT opattovaalena mir140leadstomre11downregulationandamelioratesoxaliplatintreatmentandtherapyresponseincolorectalcancerpatients